An observational study in Vitiligo, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Vitiligo is a chronic skin disorder for which new therapeutic options, including topical and oral Janus kinase (JAK) inhibitors, are emerging. In this evolving therapeutic context, long-term follow-up of patients and documentation of their treatment history are important to better understand treatment outcomes and safety in routine clinical practice.
This study is a French multicenter pilot cohort conducted as a preliminary step toward the development of a national vitiligo registry. It aims to document the clinical course of patients with vitiligo, their treatments and treatment outcomes, and adverse events occurring during treatment. The study will also collect clinical, quality-of-life and patient-reported outcome data and explore potential factors associated with treatment failure or the occurrence of adverse events.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
This study's planned enrollment of 100 is below the median of 114 across 67 observational studies indexed under Vitiligo.
Browse Vitiligo studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults and children with a diagnosis of vitiligo followed in the dermatology department of one of the participating centers in France. Participants will be included regardless of age and will receive routine clinical care for vitiligo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adults and children with a diagnosis of vitiligo followed in the dermatology department of a participating center. Participants receive routine clinical care for vitiligo. Clinical characteristics, current and previous treatments, treatment-related adverse events, disease severity, quality of life, and patient-reported outcomes are collected during follow-up
Other: Vitiligo treatments in routine clinical practice
Participants receive vitiligo treatments as part of routine clinical care. No treatment is assigned by the study protocol. Current and previous vitiligo treatments, including combination therapies, are documented during follow-up, together with clinical outcomes and treatment-related adverse events.
Clinical course of vitiligo under treatment assessed by T-VASI
Clinical course and disease severity in patients receiving currently used treatments for vitiligo, including combination therapies, will be assessed using the Total Vitiligo Area Severity Index (T-VASI). This assessment will be used to monitor changes in vitiligo severity during treatment
Time frame: Baseline, 6 months, 1 year, and 2 years
Clinical course of vitiligo under treatment assessed by sIGA
Clinical course and disease severity in patients receiving currently used treatments for vitiligo, including combination therapies, will be assessed using the Investigator Global Assessment (sIGA). This assessment will be used to monitor changes in vitiligo severity during treatment
Time frame: Baseline, 6 months, 1 year, and 2 years
Descriptive data of BMI
Descriptive data of BMI will be done using mean and median.
Time frame: Baseline
Treatment-related adverse events
Adverse events occurring in patients receiving currently used treatments for vitiligo, including combination therapies.
Time frame: Baseline, 6 months, 1 year, and 2 years
Measure of the quality of life
EQ-5D for adults participants.
Time frame: Baseline, 1 year, and 2 years
Vitiligo burden
Vitiligo burden will be assessed using the Vitiligo Impact Patient scale (VIPs).
Time frame: Baseline, 6 months, 1 year, and 2 years
Change in vitiligo disease activity assessed by the Vitiligo Signs of Activity Score (VSAS)
Vitiligo disease activity will be assessed using the Vitiligo Signs of Activity Score (VSAS). Changes in VSAS scores will be monitored over time to evaluate disease activity during follow-up.
Time frame: Baseline, 6 months, 1 year, and 2 years
Patient Self-reported Vitiligo extent (SA-VES)
Patients self-reported of disease extent will be assessed by the Self-Assessment Vitiligo Extent Score (SA-VES).This assessment will be used to monitor changes in the extent of vitiligo over time
Time frame: Baseline, 6 months, 1 year, and 2 years
Feasibility of the multicenter vitiligo registry
Number of participants enrolled, missing data, and participants lost to follow-up.
Time frame: Through study completion, up to 5 years
Measure of the quality of life
Child DLQI for pediatric participants.
Time frame: Baseline, 1 year, and 2 years
Age of participants at enrollment
Age of participants at enrollment will be recorded in years and summarized using descriptive statistics.
Time frame: Baseline
Distribution of participants by sex
The number and percentage of participants in each recorded sex category will be reported.
Time frame: Baseline
Number of participants with comorbidities
The number and percentage of participants with at least one recorded comorbidity will be reported.
Time frame: Baseline, 1 year, and 2 years
Number of participants with previous treatments for vitiligo
The number and percentage of participants who received treatment for vitiligo prior to enrollment will be reported.
Time frame: Baseline
Number of participants with a history of cancer
The number and percentage of participants with a recorded diagnosis of cancer, including skin cancer, will be reported.
Time frame: Baseline, 1 year, and 2 years
F-VASI - Facial extent of vitiligo
Facial vitiligo severity will be assessed using the Facial Vitiligo Area Severity Index (F-VASI). This assessment will be used to monitor changes in facial vitiligo severity over time
Time frame: Baseline, 6 months, 1 year, and 2 years
VNS - Patient reported Vitiligo noticeability scale (VNS)
Vitiligo noticeability will be assessed using the Vitiligo Noticeability Scale (VNS). This assessment will be used to monitor changes in the perceived noticeability of vitiligo over time
Time frame: Baseline, 6 months, 1 year, and 2 years
PHQ-4 - Patient Health Questionnaire to measure Psychological distress
Psychological distress will be assessed using the Patient Health Questionnaire-4 (PHQ-4). Changes in PHQ-4 scores will be monitored over time to evaluate psychological distress during follow-up
Time frame: Baseline, 6 months, 1 year, and 2 years
GAD-7 - Anxiety assessment
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 (GAD-7). Changes in GAD-7 scores will be monitored over time to evaluate anxiety symptoms during follow-up
Time frame: Baseline, 6 months, 1 year, and 2 years
PUSH-D - Stigma linked to vitiligo
Perceived and enacted stigma of vitiligo changes will be assessed using the PUSH-D questionnaire. Changes in PUSH-D scores will be monitored over time during follow-up
Time frame: Baseline, 6 months, 1 year, and 2 years
Plan to share: No — DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →